Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

SEROLOGICAL TESTING AND TREATMENT FOR P. VIVAX: FROM A CLUSTER-RANDOMISED TRIAL IN ETHIOPIA AND MADAGASCAR TO A MOBILE-TECHNOLOGY SUPPORTED INTERVENTION

Obiettivo

P. vivax is considered the most difficult human malaria to eliminate because of the inability of conventional diagnostics to detect individuals with latent liver forms. These individuals account for 80% of all infections and can readily infect mosquitoes. Currently countries can test knowing this has little impact or and the treat everyone which exposes individuals to drugs with potentially dangerous side effects. Parasite specific antibody responses have been shown to correlate with the likelihood of hypnozoite carriage and can be used to identify individuals who should be treated.

Aim is to implement a Cluster-Randomised Trial in Ethiopia and Madagascar to demonstrate the effectiveness of a new anti-malaria intervention based on Plasmodium vivax serological testing and treatment (PvSTATEM) with primaquine to prevent the relapse infections responsible for maintaining P. vivax transmission. Simultaneously, we will assess social and health system acceptability of such an approach as well as refine new mobile technologies which interface with point-of-care diagnostic tests and guide treatment decisions.

We aim to reduce malaria burden at both the individual and population level in two countries which experience the highest levels of P.vivax in Africa. We expect to have a significant effect in reducing morbidity and improving health. We will ensure community engagement and assess the adoption of new technologies that align with those existing in the health system. The proposal is built on equal partnership and shared capacity to address a substantial public health burden.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-RIA - HORIZON Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-HLTH-2021-DISEASE-04

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

INSTITUT PASTEUR
Contributo netto dell'UE
€ 2 656 784,74
Indirizzo
RUE DU DOCTEUR ROUX 25-28
75724 Paris
Francia
Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 2 656 784,74

Partecipanti (6)

Partner (2)